These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15218326)

  • 1. Side effects of immunosuppression--what patients really think.
    Newstead CG
    Nephron Clin Pract; 2004; 97(2):c31-2. PubMed ID: 15218326
    [No Abstract]   [Full Text] [Related]  

  • 2. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CARI guidelines. Calcineurin inhibitors in renal transplantation: adverse effects.
    Jose M;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S66-74. PubMed ID: 17316284
    [No Abstract]   [Full Text] [Related]  

  • 4. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
    Coates PT;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors.
    Grimer M;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S98-S105. PubMed ID: 17316288
    [No Abstract]   [Full Text] [Related]  

  • 7. [Controversies about the use of calcineurin inhibitors in pediatric patients].
    Dello Strologo L
    G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive strategies in renal transplantation at the beginning of the third millennium.
    Abramowicz D; Wissing KM; Broeders N
    Adv Nephrol Necker Hosp; 2000; 30():9-28. PubMed ID: 11068631
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report.
    Ghio L; Ferraresso M; Giani M; Mihatsch M; Edefonti A
    Transplant Proc; 2004 Jun; 36(5):1332-5. PubMed ID: 15251325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of renal function and cardiovascular risk factors.
    van Hooff JP; Gelens M; Boots JM; van Duijnhoven EM; Dackus J; Christiaans MH
    Transplant Proc; 2006 Sep; 38(7):1987-91. PubMed ID: 16979974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
    Jardine AG
    Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center.
    Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH
    Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin inhibitors and post-transplant weight gain.
    Ersoy A; Baran B; Ersoy C; Kahvecioglu S; Akdag I
    Nephrology (Carlton); 2008 Oct; 13(5):433-9. PubMed ID: 18331443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing transplant cancer patient survival by conversion of immunosuppressive agents.
    Chuang FR; Hsieh H; Hsu KT; Huang HF
    Transplant Proc; 1996 Jun; 28(3):1346-7. PubMed ID: 8658687
    [No Abstract]   [Full Text] [Related]  

  • 20. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.